News & Updates
Corporate announcements, scientific milestones and latest developments.
Commercial Launch: Custom PNA Synthesis for Complex Designs
Redefining the boundaries of peptide nucleic acid synthesis: unrestricted full-spectrum customization tailored to your exact molecular requirements.
Global Launch of LiverAce™ RUO Kits
Read article →Destina Secures €2.2M CDTI Funding Following EIC Seal of Excellence Award
Read article →Destina and Mecwins Awarded Funding for Early Breast Cancer Detection Project
Read article →Granada, Spain – January 13, 2026. Destina Genomics is proud to announce the commercial availability of its Unrestricted "Full-Spectrum" Custom PNA Synthesis service. By combining in-house chemistry expertise with a decade of accumulated know-how, we deliver the exact molecules your biology requires.
- Acceptance of Complex Sequences: Unlike competitors who reject designs with >5 consecutive Guanines, we accept the complex targets others refuse.
- Eliminate Redesign Cycles: You no longer have to compromise on sub-optimal target regions due to manufacturer limitations.
- Enantiomerically Enriched Units: Including specialized gamma-modified PNAs and tail modifications to fine-tune hybridization and solubility.
- Total Enzymatic Resistance: Polyamide backbone resistant to nucleases and proteases—survives in blood, serum, or saliva.
- Single-Base Precision: 100% accuracy in SNP discrimination; a single mismatch destabilizes the complex entirely.
- Higher Affinity (High Tm): Neutral backbone binds targets with far higher affinity than DNA probes, enabling lower limits of detection (LOD).
- Reliable EU Supply Chain: Based in Granada, Spain, we eliminate US/Asia shipping risks and customs delays.
- Full-Workflow Support: A single partner for design, synthesis, assay integration, and platform adaptation.
- Scientific Expertise: Direct collaboration with a team of pioneers in PNA-encoded libraries and dynamic chemistry.
"Our goal is to significantly shorten development timelines for novel therapeutic tools and next-generation diagnostics by ensuring the design is correct from the outset."
Commercial Availability of LiverAce™ RUO Kits
Granada, Spain – December 1, 2025. Destina Genomica is proud to announce the global commercial launch of our LiverAce™ Research Use Only (RUO) kits. These advanced assays are designed to provide pharmaceutical developers and CROs with high-specificity detection of liver injury biomarkers.
The LiverAce™ platform leverages our proprietary chemistry to deliver superior sensitivity without the need for amplification, streamlining workflows in pre-clinical settings.
Major Milestone: €2M Non-Dilutive Funding Secured
We are proud to announce that CDTI has backed Destina Genomica with €2 Million, validating our EIC Seal of Excellence. This funding accelerates our clinical roadmap and further de-risks our growth trajectory.
Read the full announcements:
→ Official Announcement at CDTI → Local Coverage at Granada Hoy (Español)We are thrilled to share some exciting news! Destina, in collaboration with Mecwins, has been awarded funding under the Spanish programme 'MISIONES DE CIENCIA E INNOVACIÓN', granted by the Centro para el Desarrollo Tecnológico y la Innovación (CDTI).
This support will enable us to develop 'New multi-analyte biosensor technology for the early detection of breast cancer through liquid biopsy', a joint project aimed at advancing more precise, accessible and non-invasive tools for early diagnosis.
With a grant of €495,005, we are taking another step forward in our mission to transform scientific innovation into real healthcare solutions. Together with Mecwins, we are dedicated to making cutting-edge technology accessible to those who need it most.
Thank you for joining us on this journey towards the future of early breast cancer detection!
